Related Experiment Videos
[Fluvoxamine (fevarin) in psychogenic depression]
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|January 29, 2002
Summary
Fluvoxamine effectively treated psychogenic depression with anxiety in 30 patients following trauma. Significant symptom reduction and good safety profile were observed within 8 weeks.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Psychogenic depression with anxiety can arise after severe psychological trauma, such as the loss of a loved one.
- Effective pharmacological interventions are crucial for managing these debilitating conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of fluvoxamine in treating patients with psychogenic depression and anxiety.
- To assess the impact of fluvoxamine on depressive and anxiety symptoms, including somatic and psychotic anxiety.
Main Methods:
- A study involving 30 patients diagnosed with psychogenic depression and anxiety.
- Treatment administered: fluvoxamine (100-300 mg/day) for 8 weeks.
- Assessment tools included psychopathological investigation, Clinical Global Impression Scale (CGI), Hamilton Depression Scale (HAM-D), and a Scale of Side Effects.
Main Results:
- Significant clinical improvement was observed in 63.3% of patients, starting from the second week of treatment.
- Hamilton Depression Scale scores decreased significantly from 27 to 9 (p < 0.01).
- Both anxious and depressive symptoms reduced synchronously, with somatic anxiety reduction preceding psychotic anxiety reduction.
Conclusions:
- Fluvoxamine demonstrates significant efficacy in treating psychogenic depression with anxiety following severe trauma.
- The treatment was generally well-tolerated, with transient side effects (e.g., sleepiness, nausea) reported in only 23.3% of cases during the first week.